Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

Acrivon Therapeutics (NASDAQ:
ACRV) presented three scientific posters at the AACR-NCI-EORTC International Conference in October 2025, focusing on its proprietary Generative Phosphoproteomics AP3 platform and the AP3 KaiSR ensemble model12.

Preclinical data for ACR-2316, a dual WEE1/PKMYT1 inhibitor, showed differentiated and superior pathway effects compared to other benchmark inhibitors, with the analyses pointing to a crucial role for PLK1 in the compound’s activity12.

Acrivon reported early clinical activity for ACR-2316, including a confirmed partial response observed during the dose escalation phase of its first-in-human Phase 1 study; initial clinical data will be presented later in 202512.

The AP3 KaiSR model is highlighted for its ability to globally expand actionable kinase-substrate relationships and to guide rational drug design by assessing drug effects on the intracellular protein signaling network12.

The AP3 platform aims to improve precision medicine by directly quantifying drug-regulated pathway activity levels and optimizing patient selection for targeted therapies14.

Acrivon's lead compound ACR-368 (prexasertib) is also in a Phase 2b trial, and the company's OncoSignature assay has received FDA Breakthrough Device designation25.

Sources:

1. https://www.stocktitan.net/news/ACRV/acrivon-therapeutics-highlights-its-powerful-generative-izerftf1ybo3.html

2. https://www.investing.com/news/company-news/acrivon-to-present-data-on-aidriven-cancer-drug-development-at-conference-93CH-4302921

4. https://acrivon.com/science/

5. https://www.streetinsider.com/Corporate+News/Acrivon+Therapeutics+presents+preclinical+data+for+ACR-2316+at+cancer+conference/25489111.html